*Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
†Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland
‡Division of Clinical Pharmacology, University Hospital Centre and University of Lausanne, Lausanne, Switzerland.
Supported in the framework of the Swiss HIV Cohort Study, by the Swiss National Science Foundation Grants 33CS30-134277 and 3247B0-114006.
A. C. has received travel grant and meeting expenses from Abbott, Merck Sharp & Dohme, Bristol Myers Squibb and Gilead. B. L. has been a board member of Janssen Cilag and was paid for consultancy by Gilead. H. F. G. received grants from the Swiss National Science Foundation and has been active as adviser and/or consultant for the following companies: GlaxoSmithKline, ViiV Healthcare, Abbott, Novartis, Boehringer Ingelheim, Roche, Tibotec, and Bristol-Myers Squibb. H. F. G. has received unrestricted research and educational grants from Roche, Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Tibotec, and Merck Sharp & Dohme (all money to H. F. G. went to institution). N. W. has no conflicts of interest to disclose.